Abstract:Uptake of human papillomavirus (HPV) vaccine remains low in many countries, although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are effective in the prevention of precancerous lesions of the cervix in women. Simpler immunisation schedules, such as those with fewer doses, might reduce barriers to vaccination, as may programmes that include males. To evaluate the efficacy, immunogenicity, and harms of different dose schedules and different types of HPV vaccines in females and males. We conducted electronic searches on 27 September 2018 in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) (in the Cochrane Library), and Ovid Embase. We also searched the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov (both 27 September 2018), vaccine manufacturer websites, and checked reference lists from an index of HPV studies and other relevant systematic reviews. We included randomised controlled trials (RCTs) with no language restriction. We considered studies if they enrolled HIV‐negative males or females aged 9 to 26 years, or HIV‐positive males or females of any age. We used methods recommended by Cochrane. We use the term 'control' to refer to comparator products containing an adjuvant or active vaccine and 'placebo' to refer to products that contain no adjuvant or active vaccine. Most primary outcomes in this review were clinical outcomes. However, for comparisons comparing dose schedules, the included RCTs were designed to measure antibody responses (i.e. immunogenicity) as the primary outcome, rather than clinical outcomes, since it is unethical to collect cervical samples from girls under 16 years of age. We analysed immunogenicity outcomes (i.e. geometric mean titres) with ratios of means, clinical outcomes (e.g. cancer and intraepithelial neoplasia) with risk ratios or rate ratios and, for serious adverse events and deaths, we calculated odds ratios. We rated the certainty of evidence with GRADE. We included 20 RCTs with 31,940 participants. The length of follow‐up in the included studies ranged from seven months to five years. Two doses versus three doses of HPV vaccine in 9‐ to 15‐year‐old females Antibody responses after two‐dose and three‐dose HPV vaccine schedules were similar after up to five years of follow‐up (4 RCTs, moderate‐ to high‐certainty evidence). No RCTs collected clinical outcome data. Evidence about serious adverse events in studies comparing dose schedules was of very low‐certainty owing to imprecision and indirectness (three doses 35/1159; two doses 36/1158; 4 RCTs). One death was reported in the three‐dose group (1/898) and none in the two‐dose group (0/899) (low‐certainty evidence). Interval between doses of HPV vaccine in 9‐ to 14‐year‐old females and males Antibody responses were stronger with a longer interval (6 or 12 months) between the first two doses of HPV vaccine than a shorter interval (2 or 6 months) at up to three years of follow‐up (4 RCTs, moderate‐ to high‐certainty evidence). No RCTs collected data about clinical outcomes. Evidence about serious adverse events in studies comparing intervals was of very low‐certainty, owing to imprecision and indirectness. No deaths were reported in any of the studies (0/1898, 3 RCTs, low‐certainty evidence). HPV vaccination of 10‐ to 26‐year‐old males In one RCT there was moderate‐certainty evidence that quadrivalent HPV vaccine, compared with control, reduced the incidence of external genital lesions (control 36 per 3081 person‐years; quadrivalent 6 per 3173 person‐years; rate ratio 0.16, 95% CI 0.07 to 0.38; 6254 person‐years) and anogenital warts (control 28 per 2814 person‐years; quadrivalent 3 per 2831 person‐years; rate ratio 0.11, 95% CI 0.03 to 0.38; 5645 person‐years). The quadrivalent vaccine resulted in more injection‐site adverse events, such as pain or redness, than control (537 versus 601 per 1000; risk ratio (RR) 1.12, 95% CI 1.06 to 1.18, 3895 participants, high‐certainty evidence). There was very low‐certainty evidence from two RCTs about serious adverse events with quadrivalent vaccine (control 12/2588; quadrivalent 8/2574), and about deaths (control 11/2591; quadrivalent 3/2582), owing to imprecision and indirectness. Nonavalent versus quadrivalent vaccine in 9‐ to 26‐year‐old females and males Three RCTs were included; one in females aged 9‐ to 15‐years (n = 600), one in females aged 16‐ to 26‐years (n = 14,215), and one in males aged 16‐ to 26‐years (n = 500). The RCT in 16‐ to 26‐year‐old females reported clinical outcomes. There was little to no difference in the incidence of the combined outcome of high‐grade cervical epithelial neoplasia, adenocarcinoma in situ, or cervical cancer between the HPV vaccines (quadrivalent 325/6882, nonavalent 326/6871; OR 1.00, 95% CI 0.85 to 1.16; 13,753 participants; high‐certainty evidence). The other two RCTs -Abstract Truncated-

Effects of HPV vaccination on the development of HPV-related cancers: A retrospective analysis of a United States-based cohort.

Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis

Prevalence of HPV After Introduction of the Vaccination Program in the United States

US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer

Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era

Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology

Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States

Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine

Previous History and Cigarette Smoking As Interfering Factors for the Effect of Vaccine on Human Papillomavirus Infection

Prevalence of High-Risk HPV Subtypes and Efficacy of the HPV Vaccine in Preventing Cervical Epithelial Lesions: Survey and Insights from a German Study

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

Abstract 4804: Prevalence of anal HPV infection in women attending a gynecology and colposcopy clinic: Assessing the potential impact of HPV vaccination

The Efficacy of Human Papillomavirus Prophylactic Vaccination after Conization in Preventing Cervical Intraepithelial Neoplasia Recurrence: A Prospective Observational Study in China

High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003–2006 and 2015–2018

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.

Investigating the Potential Short-term Adverse Effects of the Quadrivalent Human Papillomavirus Vaccine: A Novel Regression Discontinuity Analysis

Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women